STD AIDS Market Analysis and Reports | USA Conference Series

Market Analysis - STD AIDS 2017

HIV infection and AIDS have become a major worldwide public health problem. According to WHO approximately 35 million people worldwide living with HIV/AIDS in 2013, unaware of the outcomes. AIDS (acquired immunodeficiency syndrome) is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV) which damages the immune system and, interferes with body's ability to fight the organisms that cause disease. HIV is Sexually transmitted diseases which spread by contact with infected blood or from mother to child transmission during pregnancy, childbirth or breast-feeding. It can take years before HIV weakens the immune system to the point that the person is infected with AIDS.

With the generous response and support received from the participants of HIV/AIDS, STDs, & STIs International Conference. Conference Series proudly announces 5th International Conference on HIV/AIDS, STDs and STIs. (STD AIDS 2016) which is slated at November 13-14, 2017 Las Vegas, Nevada, USA. The theme of the conference is “Achieving HIV Epidemic Control”.

Conference Series Organizes 300 Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 400 Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members. 

Infection rates are high in Las Vegas and metro Cities. Nevada ranked 4th in the number of new AIDS cases, 7th in cumulative AIDS cases and 8th in the number of persons living with AIDS in 50 states, Miami show more than 26,000 people living with HIV/AIDS, and more than 9,500 of these (37%) have diagnosed AIDS cases. Approximately in World 123235 members are associated to HIV/AIDS, 56657 countries wise, 80 city wise. Global HIV/AIDS market, including branded products and generics, was valued at $11.3 billion in 2010.  $11.8 billion in 2011 and increase at a 4.6% compound annual growth rate (CAGR) over the 2011-2016 forecast periods to reach $14.1 billion in 2016. Branded products to treat HIV/AIDS were worth nearly $10.7 billion in 2010 and should reach $11 billion in 2011. This sector is expected to reach $13.2 billion in 2016.For more


From the beginning of the epidemic, almost 75 million people have been infected with the HIV virus and about 36 million people have died of HIV. Globally, 35.3 million [32.2–38.8 million] people were living with HIV at the end of 2012. An estimated 0.8% of adults aged 15–49 years worldwide are living with HIV, although the burden of the epidemic continues to vary considerably between countries and regions. Sub-Saharan Africa remains most severely affected, with nearly 1 in every 20 adults living with HIV and accounting for 71% of the people living with HIV worldwide.

Since the height of the epidemic in the mid-1980s, the annual number of new HIV infections in the United States has been reduced by more than two-thirds, from roughly 130,000 to 50,000 annually. Atlanta finds itself the number five ranked city when it comes to new diagnoses of HIV — a statistic that is rooted in HIV testing not being offered in places where most people get access to health care. Grady Hospital is the only emergency department in Atlanta that offers an HIV test to every patient regardless of why they are in need of care. Various universities and research institutes like EMORY university, CDC Atlanta etc performs various research based on HIV/AIDS.



Upcoming world-wide HIV AIDS Conferences

5th International Conference on HIV/AIDS, STDs & STIs, November 13-14, 2017 Las Vegas, USA

3rd International Conference on Retroviruses and Novel Drugs, July 27-28, 2017 Vancouver, Canada

4th World Congress on Infection Prevention and Control, November 13-15, 2017 Las Vegas, USA

STI & HIV World Congress Rio de Janeiro July 9-12, 2017

The annual Conference on Retroviruses and Opportunistic Infections (CROI) February 13–16, 2017

26th Annual Canadian Conference on HIV/AIDS Research – CAHR 2017, April 6-9, 2017 in Montreal, Quebec

9th IAS Conference on HIV Science (IAS 2017) 23-26 July 2017, Paris, France


Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of STD AIDS 2016, Conference Series LLC is delighted to announce the next event

Conference Series invites all the participants from all over the world to attend 5th International Conference on HIV/AIDS, STDs and STIs. (STD AIDS 2017) which is slated at November 13-14, 2017 Las Vegas, USA.

The field of HIV/AIDS and STDs (Sexually Transmitted Diseases) is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. The importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.


Opportunity to attend the presentations delivered by eminent scientists from all over the world

Selected contributions will be published in following Conference Series LLC Journal

· Journal of AIDS & Clinical Research

· Journal of HIV & Retro Virus

· Journal of Primary & Acquired Immunodeficiency Research

· Journal of Antivirals and Antiretrovirals

· Journal of Infectious Diseases & Therapy

Participation in sessions on specific topics on which the conference is expected to achieve progress

Global networking: In transferring and exchanging Ideas

Conference brings together Scientific Researchers, Safety Professionals, Regulatory Authorities, Principal Investigators, Business Entrepreneurs, and Industry Developers.

Join us in Las Vegas, USA for the leading annual HIV/AIDS event and

Find the latest developments in HIV research and therapy
Lectures by the world's prominent professionals and poster presentations at every career stage
Network STD AIDS with colleagues from more than 50 countries
Awareness on novel tools and techniques to benefit your research


Vinay Jetti
Program Manager
Phone: +1-650-268-9744

Please register through by using the following link to avail early bird discounts
register at: